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sion making for balancing citizen voice and community values against
dominant interests. Objective: To describe the use of a deliberative
forum to explore community perspectives on a complex health
problem—disinvestment. Methods: A deliberative forum of citizens
was convened in Adelaide, South Australia, to develop criteria to
support disinvestment from public funding of ineffective pathology
tests. The case study of potential disinvestment from vitamin B12/
folate pathology testing was used to shape the debate. The forum was
informed by a systematic review of B12/folate pathology test effective-
ness and expert testimony. Results: The citizens identiﬁed seven
criteria: cost of the test, potential impact on individual health/
capacity to beneﬁt, potential cost to society, public good, alternativesee front matter Copyright & 2015, International S
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ustralia.to testing, severity of the condition, and accuracy of the test. The
participants not only saw these criteria as an interdependent network
but also questioned “the authority” of policymakers to make these
decisions. Conclusions: Coherence between the criteria devised by
the forum and those described by an expert group was considerable,
the major differences being that the citizens did not consider equity
issues and the experts neglected the “cost” of social and emotional
impact of disinvestment on users and the society.
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Increasing expectations from patients, in combination with
highly marketed expensive or high-volume biomedical technol-
ogies, place pressure on health systems globally [1]. In this
environment, decision making can be found wanting if effective-
ness, budget impact, and safety are addressed with inadequate
attention to public acceptability and priorities [2,3]. Public partic-
ipation is increasingly relevant in the development of health
policy, including the assessment of new and existing health
technologies, services, and programs [4–9].
Within health technology assessment, rigorous science-based
knowledge is mostly undisputed and seen as unbiased and
objective [10–12] whereas experiential and values evidence pro-
vided by patients and lay citizens tends to be seen as subjective
and potentially biased. This “demarcationist model” [13] pre-
sumes that lay citizens do not contribute relevant knowledge and
experts and decision makers do not contribute values to decision
making. Contemporary epistemological debates challenge the
demarcationist model, arguing that normative assumptions and
science knowledge are coconstituted and that experts and non-
experts like reason using both knowledge and normative
assumptions [10,12,13]. Public deliberations, in whichparticipants consider the realities of health policy development,
can be conceptualized as collective processes of inquiry max-
imizing mutual learning and accountability within and across
expert and nonexpert groups [13].
Deliberative forums provide unique opportunities for “ordi-
nary” citizens to engage in informed deliberation, be exposed to
the perspectives and experience of others, and reach consensus
on recommendations for action [1,4,8,14–17]. Public deliberations,
using disinterested nonexpert contributors, can make explicit
nontechnical barriers and facilitators to health care policy [18]. As
such, they balance the perspectives of dominant interests with
those of less powerful citizen stakeholders [9,13,19].
This article describes the use of a deliberative forum
to explore community perspectives on a complex health
problem—disinvestment. “Disinvestment” is “the process of (par-
tially or completely) withdrawing health resources from any
existing health care practices, procedures, technologies or phar-
maceuticals that are deemed to deliver little or no health gain for
their cost, and thus are not efﬁcient health resource allocations”
[20, p. 2]. More recently, disinvestment has been rebadged as
“choosing wisely,” “reappraisal,” or “reprioritization” in the life-
cycle of technologies [21]. Disinvestment evaluates existing
health care services to redirect funding away from areas ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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tiﬁc, political, and ethical challenges: in particular, stakeholders
may be vested in current practice and such proposals may
challenge long-held beliefs and put livelihoods at risk [22]. Some
pathology services exhibit characteristics, such as low test
accuracy and wide variability in test use, that suggest that they
may be candidates for disinvestment (e.g., [23]). In particular,
vitamin B12 pathology testing has highly variable diagnostic
accuracy and inconsistent cutoff values are used across labora-
tory sites to deﬁne deﬁciency. In addition, there are geographical
differences in test use and indications of usage outside guide-
lines, and combined serum B12/folate testing grew rapidly, with
an annual growth rate in excess of 20% between 2000 and 2010
[23]. Pathology testing, as a whole, grew in excess of any other
medical activity within the Australian health system [24].
The deliberative forum reported in this article aimed to
incorporate community values in the development of criteria to
support potential disinvestment from public funding of ineffec-
tive pathology tests. A case study of vitamin B12/folate pathology
testing was used to shape the debate.Methods
The research is part of the Assessing Services and Technology
Use To Enhance Health (ASTUTE Health) study, which, using
health technology assessment methods and deliberative democ-
racy, developed, trialled, and evaluated a model to integrate
normative and scientiﬁc evidence for disinvestment from health
services with questionable safety, effectiveness, and/or cost-
effectiveness proﬁles [9]. The ASTUTE Health study also con-
ducted deliberative forums with primary care physicians, pathol-
ogists [25], and federal government policy advisors. Findings from
the ASTUTE Health study were fed back to policy advisors.
Deliberative Process
The forum was held over a weekend in Adelaide, July 2011, during
which a general medical practitioner, an epidemiologist, a health
economist, and a pathologist presented information and
responded to participants’ questions. The evidence provision
reﬂected an evidence-based approach in keeping with the format
for the forums with clinicians and policy advisors [9,25]. An
independent facilitator was engaged but withdrew because of ill
health. A research team member, with qualitative research
expertise, undertook the facilitation task. A court reporter pro-
vided immediate verbatim-identiﬁed transcription of forum
proceedings. The forum participants were asked the following
questions: 1) What things should be considered when making
decisions about how much we should publicly subsidize
B12/folate pathology tests? 2) Who should be involved in deciding
which pathology tests are publicly subsidized? The forum sched-
ule is provided online.
Recruitment of Community Forum Participants
Using stratiﬁed random sampling, jurors were recruited by an
independent recruitment company from a database drawn from
a statewide survey [26]. Sixteen participants were recruited to
fulﬁll sex, age, and household income criteria, but ﬁve withdrew
before the forum. One female participant did not return on the
second day, leaving 10 participants. An honorarium of $200 was
provided.
Theoretical Perspective and Approach to Analysis
Our analysis drew on realist approaches to discourse analysis,
particularly the thematic analysis described by Braun and Clarke[27]. Transcripts were coded independently by two authors (P.C. and
J.S.), with ongoing discussions throughout the analytic process.
Findings
The makeup of the forum mostly fulﬁlled the recruitment
criteria: half were men, age ranged from 20 to 66 years (median
41.5 years; Australian median age is 36.9 years), and four
participants had a weekly household income of less than $800
(median Australian household income).
The citizens identiﬁed seven criteria: four primary and three
secondary (Table 1). In doing so, they drew not only on the
evidence provided in the forum but also on their experience and
understanding of medical care provision and community values.
Cost of Test
Participants agreed that the cost of the test was a central point to
consider for potential disinvestment, although discussion
focused on high item test cost or high overall budgetary impact
rather than high cost by volume per se.
P8: I don’t think anyone else is saying cost in and of itself
would be one factor in isolation that we use, you would weigh
it up. [sentence omitted] With a ﬁnite amount of resources the
cost of every individual test surely is signiﬁcant, surely has
some bearing on your decision making about whether you are
going to fund or not.
Participants traded cost against potential outcomes, including
accuracy of the test or, as the following extract demonstrates, the
severity of the illness:
P11: Cost versus potential outcome. If you are spending a
thousand dollars testing for something, which could have dire
consequences for somebody, yes; maybe it’s worth it. If you
are spending $10 on a test for a nosebleed or something,
who cares?
Potential Impact
Potential for beneﬁt
Participants linked disease severity, potential life-years gained,
and overall capacity to beneﬁt. High potential for beneﬁt was
constructed as worthy of funding, with the value of quality-of-life
improvements frequently given equal footing with extension of
life.
P5: I put down quality of life. So is having the test and
subsequently having the treatment, did that prolong their
life? Is it going to make their life better?
Participants focused on capacity to beneﬁt for speciﬁc sub-
groups, including vulnerable groups.
In doing so, they drew on their understanding from interven-
tions for seasonal inﬂuenza vaccination. Participants rated access
by high-risk patient subgroups highly because these subgroups
would beneﬁt most from testing, thereby improving test accuracy
or “hit rate.” Equity arguments per se were not used to justify
these choices.
P2: Depending on the disease, depending on who is more
prevalent to actually get that type of disease … Obviously you
are going to want to have a hit rate that is going to be higher
than just the broad community. For example, the ﬂu, they say
they give it to the young, the elderly because they are the ones
that are going to be more affected by that particular type of
thing.… You have to look at the big picture of who would get
the best beneﬁt out of having the test.
Table 1 – Criteria to inform the prioritization of candidates for detailed review and potential disinvestment.
Expert criteria (Elshaug et al. [28]) Lay citizen criteria from jury
Cost of service: High cost per procedure (e.g., high item cost of the
Medicare Beneﬁts Schedule or the Pharmaceutical Beneﬁts
Scheme), high cost by volume, or an aggregate of these
Cost of test (secondary): High cost per procedure with little emphasis
on cost by volume although the overall cost was an impetus for
action. The participants traded cost per procedure against the cost
of doing nothing, the potential value associated with possible
outcomes, the availability of alternatives, and the potential for
waste if the item were funded
Potential impact:
 Likely health impact (e.g., crude estimate of quality-adjusted life-
years lost per patient)
 Likely cost effects (e.g., crude estimate of cost savings per patient;
liberation of additional resources, including downstream costs such
as theater time required for corrective procedures, and sunk costs of
human and physical capital, including costs of retraining, and costs
associated with length of hospital stay)
 Overall assessment relating to the maintenance of equity in care
should this health care intervention be displaced (e.g., access by
patient subgroups)
Potential impact:
 Potential to beneﬁt (secondary): Severity of health condition linked
to potential life-years gained and potential for improved quality of
life and/or extension of life. Possible exclusion where the condition
is related to lifestyle choices
 Cost to community (not patients) of not testing (primary): Financial
cost to the health system as well as ongoing ﬁnancial and emotional
cost to individuals and families
 Public good (secondary): In terms of preventing contagious/
infectious disease and improving quality of life
Cost-effective alternative: When a cheaper but more, or equally,
effective alternative exists, is identiﬁed, or emerges
Alternatives (primary): Including education, prevention, and
alternative treatments
Disease burden: Conditions associated with low degrees of disability or
morbidity or low rates of mortality (but excluding orphan conditions)
may inﬂuence priority differentially from those with high degrees or
rates. “Low” may reduce the potential for controversy; “high” may
represent greater scope for reinvestment/reallocation of resources
Severity (primary): With respect to both the individual and the
community
Sufﬁcient evidence available: Rigorous assessment requires robust
evidence on which decisions can be made. Although evidence is
rarely 100% conclusive, it should be available and adequate to
offer decision-making utility
Accuracy (primary but always considered in relation to other
criteria): Accuracy is related to severity of disease and relative to
other tests
Scope for time-limited funding with “pay for evidence” or “only in
research” provisions: If there is not new, adequate, or sufﬁcient
evidence, but other criteria are met and/or there is a moderate
indication of (cost-)ineffectiveness within existing evidence, then
there should be scope for “(time-limited) funding with evidence
generation” to assist decision making
This area was not discussed by the forum
Futility: An intervention that is highly unlikely to result in
“meaningful survival” or beneﬁt. For example, life-saving
treatments for those with serious dementia (especially those who
have given advance directives); procedures that require multiple
stages to which patients have poor adherence due to pain or
adverse effects; and treatments with high relapse rates
Futility: Although futility was not one of the ﬁnal criteria, some
participants deemed as futile testing where there was no potential
for effective treatment whereas others described the value of a
diagnosis
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lifestyle in vitamin B12 deﬁciency, even though the individual
may have high capacity to beneﬁt, was constructed as a possible
restrictive condition on eligibility. Participants disagreed on this
issue: some participants argued that restricting funding in this
way was discriminatory, but there was little disagreement about
the need to protect those without choice. One participant sum-
marized a stance that all supported:
P2:… this child is displaying those symptoms, being born by a
vegan parent, to me that would be an automatic inclusion. It’s
something they haven’t chosen.
Cost to community of not testing
In addition to examining the individual test cost, attention was
paid to the potential ongoing cost to the community of doing nothing.
Participants recognized that the cost of not doing a test could be
catastrophic for individuals and also very costly for society,
particularly in the long term.
P8:… we thought it was important because it was investment
in saving money down the track possibly[Two lines removed]
P1: preventative rather than cure
Community impact was directly linked to disease severity,
with ongoing emotional and ﬁnancial cost for families high-
lighted, with one participant drawing on their understanding of
the impact of spina biﬁda:
P3: The example I was thinking of was spina biﬁda. The folate
test, spina biﬁda could be prevented apparently and if you
have someone with spina biﬁda. It’s that person’s life ruined,
and probably their family, extended family. There’s cost of
care, wheelchairs, ramps, ongoing medical; the cost never
ends, whereas the initial test would have hopefully prevented
that.
The participants engaged with the potential for community
impact broadly: for example, vitamin B12 deﬁciency was
seen as having less potential for community impact than
folate deﬁciency and therefore, as the following quote indi-
cates, the imperative to fund the associated diagnostic test
was less.
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aren’t treated for it, it still affects that person in a negative
way but not to the point that it is going to impact the
community heavily.
Public good
As shown above, public good was frequently prioritized over
individual beneﬁt in many of the arguments raised by partic-
ipants. Risk to others, particularly with respect to infectious
disease diagnosis, was seen as a special case because of potential
impact on the broader community. This criterion intersected
with the criterion cost of service because participants saw that
the impact would be to amplify overall cost:
P2:…if someone has an infectious disease and it’s not brought
to the attention of that person or other professions, they are
going into the community and they are going to infect so
many more people, then they are going to have to go through
the same process with the same costings and that costing gets
blown out…
Alternatives to Testing
The participants all agreed that having “alternatives to testing”
was an important criterion. They primarily focused on inexpen-
sive noninvasive alternatives, including education and over-the-
counter medications. One forum member suggested that pre-
emptive treatment may be a solution:
P9: If you can identify suitably with a range of symptoms that
you have a certain disease without the test and you can try to
treat it beforehand, I think, then performing the test itself is a
waste of time and money.
whereas another proposed more emphasis on prevention:
P8:…how many of us wear a hat when we go outside on a 30-
degree day? How many of us wear sunscreen and how much
[sic] wear long sleeve tops when it’s hot? That is an alter-
native. Rather than testing for skin cancer, the alternative was
to provide communication, at a government level, about slip,
slop, slap. I would argue that actually may have been more
effective than doing lots of skin cancer tests.
Disease Severity
The severity of the illness and therefore its potential community
impact played a crucial role in participants’ understandings of
whether or not a test should be funded.
P3: It depends on the disease. If it’s ﬂu, ﬂu goes through the
community. If it’s Ebola that is really going to do harm, you
have to be more aggressive.
Participants related degree of disease severity and seriousness
of the treatment to test accuracy. The extract below is an
example of how participants reasoned that more burdensome
diseases and treatments might require greater test accuracy if
they are to be funded.
P4: Just expanding on that, you would want to test if you are
going to lose a kidney over it, you would want it to be
extremely accurate. While a test, say for [vitamin] B12 really
the treatment is not invasive, the treatment is not painful; we
can afford a bit more of a gap in the accuracy because it’s not
going to harm the person…
[4 lines excluded]
P8: I think there should be minimum accuracy across the
board…
[2 lines excluded]P11: That makes sense. With the common diseases with no
great consequence, your accuracy would not have to be as
great as for the more serious…
Accuracy
Accuracy (which might be more broadly construed as efﬁcacy)
was included as one of four primary criteria to consider for
disinvestment decisions but was rarely considered in isolation
from the other criteria. In the following extract, accuracy was
coupled with disease severity in deciding which of two tests
should be funded:
P1: I think for me, I’m thinking of a couple of examples where
you can say there are two tests, one is extremely accurate and
expensive, one is less accurate and expensive, there may be
some circumstances where you want the less accurate one
because you are saving resources, money.
[7 lines omitted]
P2: Depends on the consequences of the result. If you have got
a disease that is far more serious, you are going to want it to
be as accurate as possible…
In general, less accurate tests were not considered ﬁnancially
“worthwhile.”
F:…What do we need to know to feel this is accurate enough
that we are going to put money behind it and fund it?
P5: It has to be worthwhile.
P4: It can’t be hit and miss.
Test accuracy was constructed in terms of not only ﬁnancial
cost and health system impact but also emotional toll on
patients, as this participant indicated:
P4: Accuracy for the false positive, what would be the impact
on this person once this test is run… with the false positives?
How angry would those people be…. and the ﬁnancial impli-
cation of that.
F: We’ll break that down into the impact on the patient of
those false positives.
P4: It’s not just the patient; it’s the impact on the health system.
Futility
Futility was not included in the list of criteria, but some partic-
ipants argued that, without appropriate treatment, spending
money on diagnostic tests was a waste of money and would
have an adverse impact on “quality of life” whereas others
described the social value of a diagnosis. Interestingly, several
participants saw a diagnosis without the possibility of treatment
as a “personal choice” and therefore falling outside the scope of
government funding, as the following interchange demonstrates:
P6: … Why would you want to ruin your quality of life up to
the point where you do die, knowing you are going to die of
something they can’t ﬁx. You may as well die of something
they can’t ﬁx and enjoy the time.
P3: I would like to know.
P6: I’m just putting it out there.
F: At a policy level that is a question we have to ask. Are we
happy to put money into something that just does that; that
just lets you know you have this amount of time before you
die?
P8:We could spend that amount of money into research into it.
P2: That is what I am saying, it’s a personal decision whether
you want to have that deﬁned answer or not. Why would you
want to fund that when that is a personal thing? If they want
to know, that’s ﬁne, they can have the test…
P6: The question is whether you would subsidize that test.
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that because I think that is a personal choice.
Network of Criteria
The participants did not treat their derived criteria as discrete
entities. Rather, trade-offs were made continuously, with partic-
ipants’ reasoning forming a network of criteria that they used to
justify recommendations. The participants themselves were
acutely aware of this: many participants commented that the
exercise was difﬁcult because the criteria could not be considered
in isolation from one another:
P1:… these things are not standalone. You would have to take
them all together. If you found that a test was very cheap but
not very accurate, you’d have to weigh that against a test that
was more expensive but extremely accurate. You couldn’t just
take one principle by itself; you had to look at all those
principles. We felt that whatever ﬁve priorities we picked up
we couldn’t just go through a standard single checklist for
that particular item, there’d have to be a relationship between
the two.
The Nature of Disinvestment
Beyond developing a set of criteria, participants also engaged
with the nature of a potential disinvestment process. Some
participants questioned whether policymakers had “the author-
ity” to make these clinical decisions or whether the responsibility
should lie with general practitioners (GPs) either supported by “a
set guideline” or monitored through auditing. Others considered
that this meant the situation would not change and the problem
would continue. Tighter guidelines or descriptors for administer-
ing the test were seen as potential ways of disinvesting, along
with education and treatment strategies that would avoid the
need to test.
P8:…you would run through a checklist of things and not that
you would ask every person in every instance to go and do all
those, go and take a vitamin supplement ﬁrst. But it might
narrow down and it may determine – I don’t know if this is
possible…
The “checklist” for a test was seen as a way of supporting GPs
to disinvest from relatively ineffective technologies:
P8: Having that checklist takes some of the pressure off the
doctor who can say “look sorry, I can’t write out that particular
test for you because you haven’t met this criteria and that is
the national standard.”
Partial subsidies were proposed for tests that might be
considered futile or where the condition might be due to lifestyle
factors. The following quote discusses a GP-patient encounter
and a possible response to a patient who might be B12 deﬁcient
because of dietary choices.
P8: If you have had six questions and they are questions about
what types of food you eat things like that, and the patient
answers the question in such a way you go, “I’m not
surprised” you might consider if they get a full subsidy of
the test or a partial subsidy.
Some participants considered that assessing individual tests
in isolation was not the best approach for containing health care
costs.
P2: we have this big pool of money to cover all funding of all
tests.… I’m saying we should be doing [them] relative to each
other. If we have a whole group of tests, if we try and bring ourbudget down, have a group of tests that come under the same
kind of classiﬁcations, what one should be saying, is [one]
more important than another.Discussion
Citizens engaged successfully in complex deliberation on a low-
proﬁle technology, indicating that deliberative engagement is
possible for issues that may be seen as comparatively banal
because they sit outside the big moral topics that normally form
the basis of deliberative exercises (e.g., public funding of genetic
testing or nanotechnologies) [8].
Coherence between the ﬁndings of the forum and an expert-
derived list of criteria described by Elshaug et al. [28] is consid-
erable, although the forum recommendations were presented
using different language and focus. The cost of service or test,
potential impact in terms of likely health impact, capacity to
beneﬁt and cost effects, cost-effective alternatives such as pre-
vention, and disease burden in terms of disease severity all ﬁnd
their place in nontechnical language within the community
forum’s criteria.
The major differences between the list generated by the
citizens’ deliberative forum and the experts’ framework are
presented in Table 1. In particular, the forum failed to consider
equity, whereas, unlike the expert’s framework, they did consider
the “cost” of social and emotional impact of disinvestment on
users and society. The absence of the latter in the experts’
framework could be seen as a major omission. Reﬂecting their
role as potential recipients of these services, the forum partic-
ipants often put themselves in the recipient’s position to justify
chosen criteria. They also focused, however, on overall commun-
ity good and societal impact, sometimes at the expense of
individual patient well-being, and, perhaps as a consequence,
they failed to incorporate considerations of equity into their
recommendations. The participants also indicated that they
saw the criteria not as discrete entities but as an interconnected
network. In particular, accuracy played a pivotal role for the
participants in understanding whether a test was worth funding
and other factors, such as cost and severity, were reasoned in
relation to test accuracy. This is not unreasonable because test
accuracy is the ﬁrst line in the evaluation of a diagnostic test: if a
test is not accurate, testing cannot be efﬁcacious [29].
There are similarities between our study and a citizens’ jury
[16] used to develop criteria applicable to investment decision
making for new health technologies in Canada. Despite examin-
ing quite different technologies, using a more traditional jury
format and looking at investment rather than disinvestment, the
criteria proposed in the Canadian citizens’ jury were similar to
those described in our forum. There were differences, however, in
the level of priority accorded to the chosen criteria. In particular,
the Canadian jury prioritized ﬁrst those technologies with potential
to beneﬁt many. This would equate to our forum’s secondary
criteria of potential for public good. Other prioritized criteria in both
studies included enhancement of quality of life (over extension of
life span) and the lack of viable alternatives. The Canadian jury
concurred with the forum in this study that future costs associated
with not funding a technology were important. It differed on the
importance of technology unit cost—the Canadian jury indicated
that this should never be a funding criterion, whereas the Austral-
ian forum described this as an essential item for consideration.
Participants’ concerns about policymakers’ authority in dis-
investment echo senior health policy stakeholders’ own experi-
ence in negotiating “political sensitivities associated with… overt
restrictions on clinical autonomy and patient choice” [20]. The
forum participants, in common with Australian policymakers
[20], saw the need for coupling cost with quality of care in
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attention to the use of language and reasoning by the forum may
help policymakers better engage in conversations about disin-
vestment in the broader community.
Limitations
Forum participants were not provided with information about the
political barriers to disinvestment, including falling community
trust in government, nor were relevant ethical arguments
brought to their attention. This may have impacted on the nature
of the recommendations and, in particular, their inattention to
equity issues. Thus, the deliberations cannot provide guidance to
policymakers on how to manage the political aspects of dis-
investments, which will be important to overcome the inertia
inherent in the system [28]. These issues were not discussed with
the forum. In addition, the short time for deliberation and the
absence of a truly independent facilitator may have compro-
mised the ability of the participants to deliberate [8]. Although
the ﬁnal forum fulﬁlled most of the recruitment selection criteria,
diversity in the forum may have been compromised by the high
dropout rate [8].Conclusions
Participants in this study identiﬁed issues important to citizens
but neglected in the technology assessment process including the
societal impact of funding or not funding a technology and the
social and emotional fallout from inaccuracy in a test reading.
They also placed greater emphasis on the importance of public
good than on individual beneﬁt.
Taxpayers are a signiﬁcant force in the broader polity, and, as
such, their informed values, garnered in considered deliberation,
deserve respect as well as potentially providing a bulwark against
vested interests of other stakeholders. This study demonstrates
that lay citizens can participate in deliberations that form the
basis of decision making for health technology assessment even
when the technologies have low public visibility. The ability of
the forum participants to generate criteria that have universal
resonance supports the use of deliberative processes for the full
range of health technologies not only those that hold high public
value and interest.Acknowledgments
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